Vaccination to treat persistent viral infection

Virology

Volumn 268, Issue 2, 2000, Pages 411-419

  Von Herrath, Matthias G ^a   Berger, Dietmar P ^a   Homann, Dirk ^a   Tishon, Toni ^a   Sette, Alessandro ^b   Oldstone, Michael B A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b EpiImmune Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 6; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RIBAVIRIN; VIRUS NUCLEOPROTEIN; VIRUS VACCINE;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CLEARANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HELPER CELL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VACCINATION; VIRUS LOAD;

ANIMALIA; CHORIOMENINGITIS VIRUS; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

EID: 0034654361     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.0130     Document Type: Article

References (49)

1. Ahmed R., Salmi A., Butler L. D., Chiller J. M., Oldstone M. B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160:1984;521-540.
2. Alexander J., Fikes J., Hoffman S., Franke E., Sacci J., Appella E., Chicari F. V., Guidotti L. G., Chestnut R. W., Livingston B., Sette A. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 18:1998;79-92.
3. Ashton-Richardt P. A., Bandeira A., Delaney J., Van Kaer L., Pircher H. P., Zinkernagel R. M., Tonegawa S. Evidence for a differential avidity model of T-cell selection in the thymus. Cell. 76:1994;651-663.
4. Berger D. P., Homann D., Oldstone M. B. A. Defining parameters for successful immunocytotherapy of persistent viral infection. Virology. 2000.
5. + T cells in persistent infection with lymphocytic choriomeningitis virus. J. Exp. Med. 187:1998;1903-1920.
6. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S., Scognamiglio P., Boehme R., Panebianco R., Fiaccadori F., Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102:1998;968-975.
7. Borrow P., Oldstone M. B. A. Lymphocytic choriomeningitis virus. Nathanson N. Viral Pathogenesis. 1997;593-627 Lippincott-Raven, Philadelphia.
8. Buchmeier M., Welsh R., Dutko F., Oldstone M. B. A. The virology and immunobiology of LCMV infection. Adv. Immunol. 30:1980;275-331.
9. Chisari F. V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:1995;29-60.
10. Dutko F. J., Oldstone M. B. A. Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J. Gen. Virol. 64:1983;1689-1698.
11. Fisher-Hoch S. P., Khan J. A., Rehman S., Mirza S., Khurshid M., McCormick J. B. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet. 346:1995;472-475.
12. Flake A. W., Zanjani E. D. Treatment of severe combined immunodeficiency. N. Engl. J. Med. 341:1999;291-292.
13. Greenberg P. D., Riddell S. R. Deficient cellular immunity - Finding and fixing the defects. Science. 285:1999;546-551.
14. Guidotti L. G., Borrow P., Hobbs M. V., Matzke B., Gresser I., Oldstone M. B., Chisari F. V. Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc. Natl. Acad. Sci. USA. 93:1996;4589-4594.
15. Hay C. M., Ruhl D. J., Basgoz N. O., Wilson C. C., Billingsley J. M., DePasquale M. P., D'Aquila R. T., Wolinsky S. M., Crawford J. M., Montefiori D. C., Walker B. D. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J. Virol. 73:1999;5509-5519.
16. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., Wright T., Fikes J., Livingston B., Sette A., Chestnut R. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology. 30:1999;531-536.
17. Jamieson B., Somasundaram F., Ahmed R. Abrogation of tolerance to a chronic viral infection. J. Immunol. 147:1991;3521-3529.
18. Jarvis B., Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 58:1999;101-141.
19. Kagi D., Ledermann B., Burki K., Zinkernagel R. M., Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14:1996;207-232.
20. Klavinskis L., Whitton J. L., Joly E., Oldstone M. B. A. Vaccination and protection from a lethal viral infection: Identification, incorporation and use of a CTL glycoprotein epitope. Virology. 178:1990;393-400.
21. Livingston B. D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K., Guidotti L. G., Chisari F. V., Fikes J., Chesnut R. W. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 162:1999;3088-3095.
22. Mast E. E., Alter M. J., Margolis H. S. Strategies to prevent and control hepatitis B and C virus infections: A global perspective. Vaccine. 17:1999;1730-1733.
23. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
24. McKinney D. M., Lewinsohn D. A., Riddle S. R., Greenberg P. D., Mosier D. E. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. J. Immunol. 163:1999;861-867.
25. Moskophidis D., Lechner F., Hengartner H., Zinkernagel R. M. MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice. J. Immunol. 152:1994;4976-4983.
26. Moskophidis D., Lechner F., Pircher H., Zinkernagel R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 362:1993;758-761.
27. Oldstone M. B. A. Molecular mimicry and autoimmune disease. Cell. 50:1987;819-820.
28. Oldstone M. B. A., Blount P., Southern P. J., Lampert P. W. Cytoimmunotherapy for persistent virus infection: Unique clearance pattern from the central nervous system. Nature. 321:1986;239-243.
29. Planz O., Ehl S., Furrer E., Horvath E., Brundler M. A., Hengartner H., Zinkernagel R. M. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA. 94:1997;6874-6879.
30. Rehermann B., Lau D., Hoofnagle J. H., Chisari F. V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97:1996;1655-1665.
31. Riddell S. R., Greenberg P. D. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:1997;181-192.
32. Saag M. S., Kilby J. M. HIV-1 and HAART: A time to cure, a time to kill. Nat. Med. 5:1999;609-611.
33. Sprent J., Webb S. Intrathymic and extrathymic deletion of T-cells. Curr. Opin. Immunol. 7:1995;196-205.
34. Steven N. M. Epstein-Barr virus latent infection in vivo. Rev. Med. Virol. 7:1997;97-106.
35. Stitz L., Zinkernagel R. M. Immunological tolerance to a non-cytopathic virus is not inheritable in mice. Immunology. 52:1984;205-209.
36. Tan R., Xu X., Ogg G. S., Hansasuta P., Dong T., Rostron T., Luzzi G., Conlon C. P., Screaton G. R., McMichael A. J., Rowland-Jones S. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood. 93:1999;1506-1510.
37. Tishon A., Lewicki H., Rall G., von Herrath M. G., Oldstone M. B. A. An essential role for type 1 interferon-γ in terminating persistent viral infection. Virology. 212:1995;244-250.
38. Vitiello A., Ishioka G., Grey H. M., Rose R., Farness P., LaFond R., Yuan L., Chisari F. V., Furze J., Bartholomeuz R., Chesnut R. W. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest. 95:1995;341-349.
39. von Herrath M. G., Dockter J., Nerenberg M., Gairin J. E., Oldstone M. B. A. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. 180:1994a;1901-1910.
40. von Herrath M. G., Dockter J., Oldstone M. B. A. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity. 1:1994b;231-242.
41. von Herrath M. G., Guerder S., Lewicki H., Flavell R., Oldstone M. B. A. Coexpression of B7.1 and viral (self) transgenes in pancreatic β-cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity. 3:1995;727-738.
42. von Herrath, M. G, and, Whitton, J. L. 2000, Animal models using lymphocytic choriomeningitis virus, In, Current Protocols in Immunology, (, E. M. Shevach and W. Strober, Eds.), Wiley, New York, in press.
43. von Herrath M. G., Yokoyama M., Dockter J., Oldstone M. B. A., Whitton J. L. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1996;1072-1079.
44. Walter E. A., Greenberg P. D., Gilbert M. J., Finch R. J., Watanabe K. S., Thomas E. D., Riddell S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044.
45. Whitton J. L., Oldstone M. B. A. The immune response to viruses. 2000.
46. Whitton J. L., Southern P. J., Oldstone M. B. A. Analysis of the CTL responses to glycoprotein and nucleoprotein components of LCMV. J. Virol. 67:1993;2903-2907.
47. Whitton J. L., Tishon A., Lewicki H., Gebhard J., Cook T., Salvato M., Joly E., Oldstone M. B. A. Molecular analyses of a five amino acid cytotoxic T lymphocyte (CTL) epitope: An immunodominant region which induces nonreciprocal CTL cross-reactivity. J. Virol. 63:1989;4303-4310.
48. Zajac A. J., Blattman J. N., Murali-Krishna K., Sourdive D. J. D., Suresh M., Altman J. D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:1998a;2205-2213.
49. + T cells. Curr. Opin. Immunol. 10:1998b;444-449.